Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

Sandra Söderholm; Maria Anastasina; Mohammad Majharul Islam; Janne Tynell; Minna M. Poranen; Dennis H. Bamford; Jakob Stenman; Ilkka Julkunen; Ingrida Šauliene; Jef K. De Brabander; Sampsa Matikainen; Tuula A. Nyman; Xavier Saelens; Denis Kainov

doi:10.1016/j.antiviral.2015.12.011

Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

Sandra Söderholm, Maria Anastasina, Mohammad Majharul Islam, Janne Tynell, Minna M. Poranen, Dennis H. Bamford, Jakob Stenman, Ilkka Julkunen, Ingrida Šauliene, Jef K. De Brabander, Sampsa Matikainen, Tuula A. Nyman, Xavier Saelens, Denis Kainov

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.

Original language	English (US)
Pages (from-to)	69-80
Number of pages	12
Journal	Antiviral Research
Volume	126
DOIs	https://doi.org/10.1016/j.antiviral.2015.12.011
State	Published - Feb 1 2016

Keywords

Antiviral agents
Immune responses
Influenza A virus
Innate immunity
Virus-host interaction

ASJC Scopus subject areas

Pharmacology
Virology

Access to Document

10.1016/j.antiviral.2015.12.011

Cite this

Söderholm, S., Anastasina, M., Islam, M. M., Tynell, J., Poranen, M. M., Bamford, D. H., Stenman, J., Julkunen, I., Šauliene, I., De Brabander, J. K., Matikainen, S., Nyman, T. A., Saelens, X., & Kainov, D. (2016). Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine. Antiviral Research, 126, 69-80. https://doi.org/10.1016/j.antiviral.2015.12.011

@article{480b29aa37384230bf252d82a1a1bb00,

title = "Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine",

abstract = "Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.",

keywords = "Antiviral agents, Immune responses, Influenza A virus, Innate immunity, Virus-host interaction",

author = "Sandra S{\"o}derholm and Maria Anastasina and Islam, {Mohammad Majharul} and Janne Tynell and Poranen, {Minna M.} and Bamford, {Dennis H.} and Jakob Stenman and Ilkka Julkunen and Ingrida {\v S}auliene and {De Brabander}, {Jef K.} and Sampsa Matikainen and Nyman, {Tuula A.} and Xavier Saelens and Denis Kainov",

note = "Publisher Copyright: {\textcopyright} 2015 The Authors.",

year = "2016",

month = feb,

day = "1",

doi = "10.1016/j.antiviral.2015.12.011",

language = "English (US)",

volume = "126",

pages = "69--80",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

}

TY - JOUR

T1 - Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

AU - Söderholm, Sandra

AU - Anastasina, Maria

AU - Islam, Mohammad Majharul

AU - Tynell, Janne

AU - Poranen, Minna M.

AU - Bamford, Dennis H.

AU - Stenman, Jakob

AU - Julkunen, Ilkka

AU - Šauliene, Ingrida

AU - De Brabander, Jef K.

AU - Matikainen, Sampsa

AU - Nyman, Tuula A.

AU - Saelens, Xavier

AU - Kainov, Denis

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.

AB - Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNα)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections.

KW - Antiviral agents

KW - Immune responses

KW - Influenza A virus

KW - Innate immunity

KW - Virus-host interaction

UR - http://www.scopus.com/inward/record.url?scp=84952845480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952845480&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2015.12.011

DO - 10.1016/j.antiviral.2015.12.011

M3 - Article

C2 - 26738783

AN - SCOPUS:84952845480

SN - 0166-3542

VL - 126

SP - 69

EP - 80

JO - Antiviral Research

JF - Antiviral Research

ER -

Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this